2[1]Morris JB,Christopher R,Alain C,et al.Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the international nifedipine GITS study:intervention as a goal in hypertension treatment (INSIGHT).Lancet,2000,356:366-3 72.
3[2]Collins R,Peto R,MacMahon S,et al.Blood pressure,stroke and coronary heart disease,part 2 short-term reductions in blood pressure:ove rview of randomised drug trials in their epidemiological context. Lancet,1990,32 5:827-838.
4[3]Ramsay LE,Williams B,Johnston GD,et al.British Hyperte nsion Society guidelines for hypertension management 1999,summary.Br Med J,1999, 319:630-635.
5[4]Brown MJ,Castaigne A,Deleeuw PW,et al.Influence of dia betes and type of hypertension on the response to antihypertensive treatment.Hyp ertension,2000,35:1038-1042.
6[5]Pahor M,Guralnik JM,Corti MC,et al.Long-term surviva l and use of antihypertensive medications in older persons.J Am Geriatr Soc,1995 ,43:1191-1197.
7[6]Pahor M,Guralnik JM,Ferruci L,et al.Calcium-channel blockade and incidence of cancer in aged populations.Lancet,1996,348:493-499.
8[7]Gress TW,Nieto FJ,Shahar E,et al.Hypertension and anti hypertensive therapy as risk factors for type 2 diabetes mellitus.N Engl J Med,2 000,342:905-912.
